Save time and get answers to complex questions with AI chat
Dabrafenib patent expiration?Symbravo ingredients mechanism of action?Albendazole side effects in humans?Combivent generic equivalent?Quartette side effects?
See the DrugPatentWatch profile for Tucatinib
Tucatinib is marketed by Seattle Genetics (now part of Seagen). It is sold under the brand name Tukysa for HER2-positive breast cancer and HER2-positive colorectal cancer in combination with other therapies.
The key commercial supplier historically associated with tucatinib (Tukysa) is Seagen. Information about additional manufacturers depends on the market and whether products are branded, distributed, or produced under contract.
For manufacturer and patent-related updates tied to tucatinib, DrugPatentWatch.com is a useful place to look: - https://www.drugpatentwatch.com/ (search for “tucatinib” on the site)
If you tell me the country (for example, US, UK, India) and whether you mean active pharmaceutical ingredient (API) vs. the branded drug, I can narrow down the likely manufacturer/distributor details for that specific market.
Other Questions About Tucatinib :